Squarepoint Ops LLC Purchases 4,384 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Squarepoint Ops LLC increased its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 36.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,534 shares of the company’s stock after acquiring an additional 4,384 shares during the period. Squarepoint Ops LLC’s holdings in Zevra Therapeutics were worth $138,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in shares of Zevra Therapeutics during the fourth quarter worth about $53,000. ProShare Advisors LLC bought a new stake in Zevra Therapeutics during the fourth quarter valued at approximately $145,000. Invesco Ltd. grew its stake in Zevra Therapeutics by 19.6% in the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company’s stock worth $153,000 after buying an additional 3,007 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Zevra Therapeutics by 51.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company’s stock worth $172,000 after buying an additional 6,966 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. bought a new position in shares of Zevra Therapeutics in the 4th quarter worth $209,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Trading Down 0.8%

ZVRA opened at $9.19 on Tuesday. The stock has a 50-day moving average of $7.79 and a 200 day moving average of $8.06. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a 12 month low of $4.20 and a 12 month high of $9.76. The firm has a market cap of $502.51 million, a P/E ratio of -4.66 and a beta of 2.01.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $20.40 million for the quarter, compared to analysts’ expectations of $16.96 million. During the same period in the prior year, the business posted ($0.40) earnings per share. As a group, research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a report on Thursday, March 13th. JMP Securities set a $18.00 target price on Zevra Therapeutics in a research note on Wednesday, March 12th. Guggenheim increased their price target on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Finally, Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Zevra Therapeutics currently has an average rating of “Buy” and a consensus target price of $22.29.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode bought 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Wednesday, March 19th. The stock was purchased at an average price of $7.96 per share, with a total value of $79,600.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at approximately $318,400. This trade represents a 33.33% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.40% of the stock is currently owned by company insiders.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.